Stenocare

0,80 DKK

-7,39 %

Mindre end 1K følgere

STENO

First North Denmark

Biotechnology & Pharmaceuticals

Health Care

Oversigt

Finansielt overblik og estimater

Ejerskab

Dividend

Investorkonsensus

-7,39 %

-42,71 %

-45,81 %

-45,44 %

-27,75 %

+85,65 %

-83,10 %

-90,12 %

-94,12 %

Stenocare opererer inden for sundhedssektoren. Virksomheden specialiserer sig i udvikling af medicinsk cannabis. Stenocare er en af de første aktører, der er begyndt at sælge medicinske cannabisolier i Danmark. Visionen er også at adressere andre europæiske markeder med sit produktsortiment. Stenocares hovedkvarter ligger i Randers.

Markedsværdi

34,81 mio. DKK

Aktieomsætning

136,24 t DKK

Omsætning

7,02 mio.

EBIT %

-25,26 %

P/E

-

Udbytteafkast, %

-

Omsætning og EBIT-margin

Omsætning mio.

EBIT-% (adj.)

EPS og udbytte

EPS (adj.)

Udbytte %

Finanskalender

20.8

2026

Delårsrapport Q2'26

29.10

2026

Delårsrapport Q3'26

Alle

Selskabsmeddelelser

Eksterne analyser

ViserAlle indholdstyper

Selskabsmeddelelse26.2.2026, 07.00

STENOCARE: Interim report fourth quarter and Financial Statement Release 2025

Pressemeddelelse11.2.2026, 07.00

STENOCARE A/S positions for First-Mover Advantage in France With Strategic Partnership, Product Filing, and National Distribution Partnership

Pressemeddelelse27.1.2026, 15.27

STENOCARE: Stenocare Kicks Off Strategic Partnership with WEECO to Launch New Astrum Oil Product in Germany

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto

Følgere og notifikationer om fulgte virksomheder

Analytikerkommentarer og anbefalinger

Værktøj til at sammenligne aktier og andre populære værktøjer

Selskabsmeddelelse30.12.2025, 10.19

Trading in STENOCARE shares by closely related party to board member

Pressemeddelelse21.11.2025, 05.41

BioStock: Stenocare acquires Canngros

Pressemeddelelse19.11.2025, 18.56

STENOCARE share analyst's comments on the CannGros acquisition

Selskabsmeddelelse18.11.2025, 08.59

STENOCARE: Correction of total shares issued and total nominal share capital:

Selskabsmeddelelse17.11.2025, 16.56

STENOCARE A/S acquires CannGros ApS and add DKK 4-6 million in annual revenue and supports 2026 break even goal

Selskabsmeddelelse17.11.2025, 16.01

STENOCARE A/S acquires CannGros ApS and add DKK 4-6 million in annual revenue and supports 2026 break even goal

Selskabsmeddelelse22.10.2025, 06.00

STENOCARE: Interim report third quarter 2025

Selskabsmeddelelse27.8.2025, 19.30

Trading in STENOCARE shares by closely related party to board member

Selskabsmeddelelse21.8.2025, 06.00

STENOCARE: Interim report second quarter 2025

Eksterne analyser19.5.2025, 08.05

STENOCARE: Time to Capitalize on STENOCARE 3.0 - Analyst Group

STENOCARE A/S (“STENOCARE” or the “Company”) is a medical cannabis trading company with products approved and available for patients in six countries. The Company has recently launched a premium product, Astrum oil, which Analyst Group sees as an important...

Selskabsmeddelelse15.5.2025, 09.36

Communiqué from the Annual General Meeting of STENOCARE

Eksterne analyser9.5.2025, 05.25

Analyst Group Comment on STENOCARE's Q1-report

STENOCARE A/S (STENOCARE or the “Company”) published on May 8th the Company’s Q1-report for 2025.

Selskabsmeddelelse8.5.2025, 06.00

STENOCARE: Interim report first quarter 2025

Pressemeddelelse2.5.2025, 12.35

Medical Cannabis Made Permanent in Denmark: Major Milestone for Patients and STENOCARE

Selskabsmeddelelse22.4.2025, 13.01

Notice to Annual General Meeting in STENOCARE A/S

Eksterne analyser4.4.2025, 07.20

Analyst Group Comment on STENOCARE ASTRUM 10-10 Oil Being Approved for Reimbursement in Germany

On April 4th, STENOCARE announced that the innovative ASTRUM 10-10 has obtained for approval for reimbursement in Germany through major health insurance providers. Starting in April 2025, approximately 14 million insured individuals will be eligible ...

Pressemeddelelse3.4.2025, 06.00

STENOCARE ASTRUM 10-10 Oil Product Approved for Reimbursement in Germany

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.